200 related articles for article (PubMed ID: 21506597)
1. Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.
Duke CB; Jones A; Bohl CE; Dalton JT; Miller DD
J Med Chem; 2011 Jun; 54(11):3973-6. PubMed ID: 21506597
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure, docking study and structure-activity relationship of carborane-containing androgen receptor antagonist 3-(12-hydroxymethyl-1,12-dicarba-closo-dodecaboran-1-yl)benzonitrile.
Ohta K; Goto T; Fujii S; Kawahata M; Oda A; Ohta S; Yamaguchi K; Hirono S; Endo Y
Bioorg Med Chem; 2011 Jun; 19(11):3540-8. PubMed ID: 21536446
[TBL] [Abstract][Full Text] [Related]
3. Subtle structural changes in tetrahydroquinolines, a new class of nonsteroidal selective androgen receptor modulators, induce different functions.
Nagata N; Kawai K; Nakanishi I
J Chem Inf Model; 2012 Aug; 52(8):2257-64. PubMed ID: 22794275
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor antagonists: a patent review (2008-2011).
Mohler ML; Coss CC; Duke CB; Patil SA; Miller DD; Dalton JT
Expert Opin Ther Pat; 2012 May; 22(5):541-65. PubMed ID: 22583332
[TBL] [Abstract][Full Text] [Related]
5. Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer.
Fletterick RJ
BJU Int; 2005 Dec; 96 Suppl 2():2-9. PubMed ID: 16359432
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor as a therapeutic target.
Gao W
Adv Drug Deliv Rev; 2010 Oct; 62(13):1277-84. PubMed ID: 20708648
[TBL] [Abstract][Full Text] [Related]
7. Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.
Guo C; Pairish M; Linton A; Kephart S; Ornelas M; Nagata A; Burke B; Dong L; Engebretsen J; Fanjul AN
Bioorg Med Chem Lett; 2012 Apr; 22(7):2572-8. PubMed ID: 22377517
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
Yamamoto S; Matsunaga N; Hitaka T; Yamada M; Hara T; Miyazaki J; Santou T; Kusaka M; Yamaoka M; Kanzaki N; Furuya S; Tasaka A; Hamamura K; Ito M
Bioorg Med Chem; 2012 Jan; 20(1):422-34. PubMed ID: 22094279
[TBL] [Abstract][Full Text] [Related]
9. Discovery of diarylhydantoins as new selective androgen receptor modulators.
Nique F; Hebbe S; Peixoto C; Annoot D; Lefrançois JM; Duval E; Michoux L; Triballeau N; Lemoullec JM; Mollat P; Thauvin M; Prangé T; Minet D; Clément-Lacroix P; Robin-Jagerschmidt C; Fleury D; Guédin D; Deprez P
J Med Chem; 2012 Oct; 55(19):8225-35. PubMed ID: 22897611
[TBL] [Abstract][Full Text] [Related]
10. Pantolactams as androgen receptor antagonists for the topical suppression of sebum production.
Sexton KE; Barrett S; Bridgwood K; Carroll M; Dettling D; Du D; Fakhoury S; Fedij V; Hu LY; Kostlan C; Pocalyko D; Raheja N; Smith Y; Shanmugasundaram V; Wade K
Bioorg Med Chem Lett; 2011 Sep; 21(18):5230-3. PubMed ID: 21831636
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.
Yamamoto S; Tomita N; Suzuki Y; Suzaki T; Kaku T; Hara T; Yamaoka M; Kanzaki N; Hasuoka A; Baba A; Ito M
Bioorg Med Chem; 2012 Apr; 20(7):2338-52. PubMed ID: 22391033
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.
Yoshino H; Sato H; Shiraishi T; Tachibana K; Emura T; Honma A; Ishikura N; Tsunenari T; Watanabe M; Nishimoto A; Nakamura R; Nakagawa T; Ohta M; Takata N; Furumoto K; Kimura K; Kawata H
Bioorg Med Chem; 2010 Dec; 18(23):8150-7. PubMed ID: 21050768
[TBL] [Abstract][Full Text] [Related]
13. SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer.
Yang SH; Song CH; Van HT; Park E; Khadka DB; Gong EY; Lee K; Cho WJ
J Med Chem; 2013 Apr; 56(8):3414-8. PubMed ID: 23527816
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance.
Zhou J; Geng G; Shi Q; Sauriol F; Wu JH
J Med Chem; 2009 Sep; 52(17):5546-50. PubMed ID: 19725582
[TBL] [Abstract][Full Text] [Related]
15. Circumventing anti-androgen resistance by molecular design.
McGinley PL; Koh JT
J Am Chem Soc; 2007 Apr; 129(13):3822-3. PubMed ID: 17348658
[TBL] [Abstract][Full Text] [Related]
16. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
Guerrini A; Tesei A; Ferroni C; Paganelli G; Zamagni A; Carloni S; Di Donato M; Castoria G; Leonetti C; Porru M; De Cesare M; Zaffaroni N; Beretta GL; Del Rio A; Varchi G
J Med Chem; 2014 Sep; 57(17):7263-79. PubMed ID: 25121586
[TBL] [Abstract][Full Text] [Related]
17. Novel selective anti-androgens with a diphenylpentane skeleton.
Maruyama K; Noguchi-Yachide T; Sugita K; Hashimoto Y; Ishikawa M
Bioorg Med Chem Lett; 2010 Nov; 20(22):6661-6. PubMed ID: 20888766
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel androgen receptor antagonists with sterically bulky icosahedral carboranes.
Goto T; Ohta K; Suzuki T; Ohta S; Endo Y
Bioorg Med Chem; 2005 Dec; 13(23):6414-24. PubMed ID: 16099660
[TBL] [Abstract][Full Text] [Related]
20. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
